Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Novartis India Ltd Fundamentals

Market Cap
₹ 2713.77 Cr
P/E Ratio (TTM)
31.86
P/B Ratio
3.64
Debt to Equity
0.03
ROE
14.09
EPS (TTM)
34.50
Dividend Yield
2.27 %
Book Value
301.66

Click here to know more about Fundamentals

Novartis India Ltd Financials

Novartis India Ltd Financials

Novartis India Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 70.68 % 70.68 % 70.68 % 70.68 %
Retail 22.95 % 23.21 % 23.29 % 23.08 %
Others 6.18 % 5.91 % 5.71 % 6.00 %
FII 0.19 % 0.20 % 0.32 % 0.24 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

70.68%

Retail

22.95%

Others

6.18%

FII

0.19%

Mutual Funds

0.00%

Promoters

70.68%

Retail

23.21%

Others

5.91%

FII

0.20%

Mutual Funds

0.00%

Promoters

70.68%

Retail

23.29%

Others

5.71%

FII

0.32%

Mutual Funds

0.00%

Promoters

70.68%

Retail

23.08%

Others

6.00%

FII

0.24%

Mutual Funds

0.00%

Resistance and Support

₹679.60

PIVOT

resistance-arrow
Resistance
First Resistance₹690.850
Second Resistance₹709.450
Third Resistance₹720.700
support-arrow
Support
First Support₹661.000
Second Support₹649.750
Third Support₹631.150

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day21,7476,37553.86
Week11,8377,534-41.22
1 Month11,8376,943-41.22
6 Months000.00

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is focused on manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates in four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz. The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886. In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years. In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd. joined to form Novartis. In the year 1998, the company had set-up the Novartis Institute for Functional Genomics. During the year 2000, Novartis acquired the products Famvir and Vectavir/Denavir from SmithKline Beecham also in the same year, the company started to provide treatment to leprosy patients worldwide through World Health Organisation (WHO). Also in 2000, NIL had started JEET (Joint Effort to Eradicate Tuberculosis) with the aim of increasing awareness among TB patents and to involve doctors more actively in the fight against disease. After a year, Novartis Respiratory Research Centre, the largest of its kind in the world, was opened in Horsham (UK) in 2001 and also during the same year Novartis had entered into a partnership with the WHO to stem the spread of malaria in areas of the world were the diseases in endemic. The Glivec, a drug was launched by the company in April of the year 2002 in India. The Company bagged TERI corporate social responsibility award for the year 2002-03. Novartis united its generics businesses under one single global brand in the name of Sandoz during the year 2003 and also in the same year, the company was granted Exclusive Marketing Rights (EMR) for Glivec. In the year of 2005, the company and Astex Therapeutics formed an alliance to focus on novel cell cycle anti-cancer drugs and also NIL had debuted Citro-macalvit & Trioptal as new products for the year. During the year 2006 alone Novartis had spent about USD 755 million on research into neglected diseases and various patient-access programs. In August of the same year 2006, the company had filed a petition in the Madras High Court challenging the rejection of the Glivec patent and the same petition was dismissed by the Madras high court in August of the year 2007. In the identical year of 2007, NIL sold its Medical Nutrition business to Nestle. The Company had launched a new marketing initiative on National scale in September of the year 2008 named Arogya Parivar targeting the healthcare needs of villagers. New products and line extensions introduced during the period 2009-10 were Relmus , Coderan for Pain & Inflammation, Vinlep for Epilepsy and Givec HGC 100 mg for Oncology. Otrivin was re-launched as an OTC remedy in a new spray format and positioned as a convenient alternative to tablets. During the period 2013-14, the Company signed a Distribution Agreement with Nutri-Ad International NV, Belgium, for marketing and distribution of their poultry feed supplements in India and started distributing Adimix 30 Coated, Eurotiox 32 Premix, Salmonil Dry, Toxynil Dry and Nutrilac IGA. The Company also signed a Marketing and Distribution Agreement with Johnson and Johnson Limited, India, for marketing and distribution of their Ethicon sutures under the brand names Mersutures Catgut 1, Ethilon Nylon and Mersilk Silk for veterinary use in the cattle and canine segments.

Managing Director

1947

Founded

Sanjay Murdeshwar

NSE Symbol

NOVARTIND

Novartis India Ltd Management

NameDesignation
C SnookChairman (Non-Executive)
Jai HiremathIndependent Director
Sandra MartryesIndependent Director
Sanjay MurdeshwarVice Chairman & M.D.
SANKER PARAMESWARANIndependent Director
Shilpa JoshiWhole Time Director & CFO
Chandni MaruCompany Sec. & Compli. Officer

Novartis India Ltd News

Novartis to pay final dividend
On or after 05 August 2024
Novartis India to conduct AGM
On 31 July 2024
Board of Novartis India recommends Final Dividend
Of Rs.25 per share
Novartis India standalone net profit declines 41.33% in the March 2024 quarter
Sales rise 6.62% to Rs 81.17 crore
Novartis India to conduct board meeting
On 10 May 2024
Novartis India Ltd leads losers in 'B' group
Pritish Nandy Communications Ltd, DB (International) Stock Brokers Ltd, Sarthak Metals Ltd and MIC Electronics Ltd are among the other losers in the BSE's 'B' group today, 20 February 2024.
Novartis India standalone net profit rises 249.15% in the December 2023 quarter
Sales rise 5.45% to Rs 84.54 crore
Novartis India to convene board meeting
On 25 January 2024
Novartis India standalone net profit rises 29.05% in the September 2023 quarter
Sales decline 22.42% to Rs 78.76 crore
Novartis India to announce Quarterly Result
On 27 October 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Adani Enterprises Ltd₹ 358068.65 Cr
₹ 3,223.00
(2.61 %)
125.89
Aegis Logistics Ltd₹ 22263.93 Cr
₹ 639.05
(0.75 %)
50.48
Cello World Ltd₹ 19477.5 Cr
₹ 925.65
(0.86 %)
0.00
Redington Ltd₹ 16514.98 Cr
₹ 209.45
(-0.85 %)
15.27
Honasa Consumer Ltd₹ 13825.77 Cr
₹ 419.15
(-1.70 %)
145.05

Novartis India Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Novartis India Ltd shares in BlinkX

Novartis India Ltd's P/E ratio is 31.86 times as of October 25, 2023 at 04:00 PM.

Novartis India Ltd's most recent financial reports indicate a price-to-book ratio of 3.64, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Novartis India Ltd's market is 2,714 Cr as on October 25, 2023 at 04:00 PM.

The current financial records of Novartis India Ltd show a 14.09% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Novartis India Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Novartis India Ltd stands at 70.68%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 0.20% to 0.19%.